BioAtla Investor Presentation Deck

Potential Market Opportunity in Metastatic Melanoma ~1.3MM ~50% bicatla people in the U.S. living with melanoma¹ do not respond to PD-1 therapy in 1L setting² ~100K 30-40% newly diagnosed invasive cases / year (U.S.)¹ 1L, first line; 2L+, second line or greater; ICIS - Immune checkpoint inhibitors. initial responders progress² Available Treatment 1L: ICIs 33% - 50% ORR³; (BRAF / Mek inhibitors for BRAF+) 2L+: ICIS 9% -28% ORR (mono- combo, respectively)4 ¹Clarivate, Disease Landscape and Forecast: Malignant Melanoma (2022). www.cancer.net; www.cancer.org; 2Oncology (Williston Park). 33(4):141-8. ³Keytruda USPI accessed June 2022; Opdivo USPI accessed June 2022. 4VanderWalde A, Moon J, Bellasea S, et al. Ipilimumab plus nivolumab versus ipilimumab alone in patients with metastatic or unresectable melanoma that did not respond to anti-PD-1 therapy. Presented at: 2022 AACR Annual Meeting; April 8-13, 2022; New Orleans, LA. Abstract CT013. BioAtla| Overview 45

View entire presentation